prulifloxacin has been researched along with Respiratory Tract Infections in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Falagas, ME; Karageorgopoulos, DE; Maraki, S; Samonis, G; Schito, GC; Vatopoulos, AC | 1 |
| De Vecchi, E; Drago, L; Mattina, R; Nicola, L | 1 |
| Falagas, ME; Polyzos, KA; Rafailidis, PI; Sgouros, K | 1 |
| Chen, Y; Huang, W; Li, Q; Lu, G; Lv, X; Sun, Y; Wu, G; Wu, X; Wu, Y; Yang, H; Zhang, G | 1 |
| Mirelis, B; Prats, G; Rossi, V; Salvatori, E | 1 |
| Eda, T; Hosaka, M; Hoshino, K; Inoue, M; Kaieda, S; Kitasato, H; Kuga, A; Okamoto, R; Sato, Y; Seto, I | 1 |
| Kimura, K; Kise, M; Kitano, M; Matsuda, M; Nishino, T; Otsuki, M; Ozaki, M; Segawa, J; Shibata, K; Tomii, Y | 1 |
2 review(s) available for prulifloxacin and Respiratory Tract Infections
| Article | Year |
|---|---|
Prulifloxacin: a review focusing on its use beyond respiratory and urinary tract infections.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Dioxolanes; Fluoroquinolones; Humans; Piperazines; Randomized Controlled Trials as Topic; Respiratory Tract Infections; Urinary Tract Infections | 2011 |
Prulifloxacin: a new antibacterial fluoroquinolone.
Topics: Anti-Bacterial Agents; Bacterial Infections; Clinical Trials as Topic; Community-Acquired Infections; Cross Infection; Dioxolanes; Drug Resistance, Bacterial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Piperazines; Quinolones; Respiratory Tract Infections; Treatment Outcome | 2006 |
1 trial(s) available for prulifloxacin and Respiratory Tract Infections
| Article | Year |
|---|---|
Prulifloxacin versus levofloxacin in the treatment of respiratory and urinary tract infections: a multicentre, double-blind, randomized controlled clinical trial.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Dioxolanes; Disk Diffusion Antimicrobial Tests; Double-Blind Method; Female; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Piperazines; Respiratory Tract Infections; Treatment Outcome; Urinary Tract Infections; Young Adult | 2012 |
5 other study(ies) available for prulifloxacin and Respiratory Tract Infections
| Article | Year |
|---|---|
Antimicrobial activity of prulifloxacin in comparison with other fluoroquinolones against community-acquired urinary and respiratory pathogens isolated in Greece.
Topics: Adult; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Community-Acquired Infections; Dioxolanes; Female; Fluoroquinolones; Greece; Humans; Male; Microbial Sensitivity Tests; Piperazines; Prospective Studies; Respiratory Tract Infections; Urinary Tract Infections | 2013 |
In vitro selection of resistance in Escherichia coli and Klebsiella spp. at in vivo fluoroquinolone concentrations.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Ciprofloxacin; Dioxolanes; DNA Gyrase; DNA Mutational Analysis; DNA Topoisomerase IV; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Fluoroquinolones; Humans; Klebsiella; Klebsiella Infections; Levofloxacin; Microbial Sensitivity Tests; Mutation; Ofloxacin; Piperazines; Respiratory Tract Infections; Selection, Genetic; Urinary Tract Infections | 2010 |
Prulifloxacin. NAD-441A, NM 441, Quisnon.
Topics: Animals; Anti-Infective Agents; Dioxolanes; Drug Interactions; Enteritis; Fluoroquinolones; Humans; Male; Mice; Piperazines; Prostatitis; Quinolones; Respiratory Tract Infections; Surgical Wound Infection | 2002 |
[In vitro antibacterial activity of prulifloxacin, a new oral quinolone, and comparative susceptibility rate at clinical breakpoint MIC].
Topics: Anti-Infective Agents; Bacteria; Dioxolanes; Drug Resistance, Microbial; Fluoroquinolones; Humans; Levofloxacin; Ofloxacin; Piperazines; Quinolones; Respiratory Tract Infections; Sepsis | 2000 |
In vivo evaluation of NM441, a new thiazeto-quinoline derivative.
Topics: Administration, Oral; Animals; Anti-Infective Agents; Ciprofloxacin; Dioxolanes; Dogs; Drug Evaluation, Preclinical; Enoxacin; Female; Fluoroquinolones; Male; Mice; Microbial Sensitivity Tests; Ofloxacin; Piperazines; Prodrugs; Quinolones; Respiratory Tract Infections; Streptococcal Infections; Urinary Tract Infections | 1991 |